{"protocolSection":{"identificationModule":{"nctId":"NCT04213807","orgStudyIdInfo":{"id":"ANT-004"},"organization":{"fullName":"Anthos Therapeutics, Inc.","class":"INDUSTRY"},"briefTitle":"A Dose-range Finding Study of MAA868 in Patients With Atrial Fibrillation","officialTitle":"A Randomized, Placebo-controlled, Dose-range Finding Study to Assess the Pharmacokinetic and Pharmacodynamic Parameters, Safety, Tolerability, and Immunogenicity of MAA868 in Patients With Atrial Fibrillation"},"statusModule":{"statusVerifiedDate":"2021-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2019-12-11","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2020-12-29","type":"ACTUAL"},"completionDateStruct":{"date":"2021-03-08","type":"ACTUAL"},"studyFirstSubmitDate":"2019-12-23","studyFirstSubmitQcDate":"2019-12-26","studyFirstPostDateStruct":{"date":"2019-12-30","type":"ACTUAL"},"resultsFirstSubmitDate":"2021-11-09","resultsFirstSubmitQcDate":"2021-11-09","resultsFirstPostDateStruct":{"date":"2021-12-07","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-12-24","lastUpdatePostDateStruct":{"date":"2022-01-11","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Anthos Therapeutics, Inc.","class":"INDUSTRY"},"collaborators":[{"name":"Covance","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study is a multicenter, randomized, subject and Investigator-blinded, placebo-controlled, parallel-group, multiple ascending dose-ranging study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) effects of MAA868 in patients with atrial fibrillation (AF) or flutter at low risk of thromboembolic stroke or peripheral embolism."},"conditionsModule":{"conditions":["Atrial Fibrillation"],"keywords":["atrial fibrillation","flutter","paroxysmal atrial fibrillation","stroke","cardiac arrhythmia"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":28,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"MAA868","type":"EXPERIMENTAL","description":"Subcutaneous injection on Day 1 with two subsequent monthly injections","interventionNames":["Biological: MAA868 Cohort 1","Biological: MAA868 Cohort 2","Biological: MAA868 Cohort 3"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Subcutaneous injection: Placebo on Day 1 with two subsequent monthly injections","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"MAA868 Cohort 1","description":"Subcutaneous injection: low dose","armGroupLabels":["MAA868"]},{"type":"BIOLOGICAL","name":"MAA868 Cohort 2","description":"Subcutaneous injection: high dose","armGroupLabels":["MAA868"]},{"type":"BIOLOGICAL","name":"MAA868 Cohort 3","description":"Subcutaneous injection: Dose to be determined.","armGroupLabels":["MAA868"]},{"type":"OTHER","name":"Placebo","description":"Subcutaneous injection: Placebo","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants That Achieved More Than or Equal to 50%, 80%, and 90% Factor XI Inhibition at Trough After the Third Dose (Day 91) at Different Dose Levels of MAA868","description":"Number of participants achieving more than or equal to 50%, 80%, and 90% inhibition of factor XI (less than 50%, 20%, or 10% free factor XI) at trough after the third dose on Day 91 at different dose levels of MAA868","timeFrame":"Day 91"}],"secondaryOutcomes":[{"measure":"Number of Participants Achieving More Than or Equal to 50%, 80%, and 90% Factor XI Inhibition at Trough After First (Day 31) and Second Doses (Day 61) at Different Dose Levels of MAA868","description":"Number of participants achieving more than or equal to 50%, 80%, and 90% inhibition of factor XI (less than 50%, 20%, or 10% free factor XI) at trough on Day 31 (after first dose) and Day 61 (after second dose) at different dose levels of MAA868","timeFrame":"Day 31 and Day 61"},{"measure":"Overall Number of Participants Who Experienced Adverse Events, Including Serious Adverse Events, During the Treatment Period and Through End of Study","description":"Overall number of participants who experienced adverse events following multiple subcutaneous administration of MAA868 compared to placebo in participants with atrial fibrillation or atrial flutter","timeFrame":"Day 1 through end of study, up to 170 days"},{"measure":"Incidence of Major Bleeding Events, Clinically Relevant Non-major Bleeding Events and Total Bleeding With MAA868 Relative to Placebo","description":"Occurrence of confirmed major bleeding events, clinically relevant non-major bleeding events and total bleeding events during the treatment period","timeFrame":"Day 1 through end of study, up to 170 days"},{"measure":"Immunogenicity of MAA868","description":"Number of participants with anti-drug (MAA868) antibodies for all participants who received MAA868 120 mg or MAA868 180 mg.\n\n\"Non-evaluable observation\" refers to participants who had no sample collected (due to no visit or remote visit) or for whom the sample was not frozen.","timeFrame":"Days 1, 31, 61, 71, 91, 121 and 170"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female patients â‰¥ 18 and \\< 85 years old with paroxysmal atrial fibrillation (PAF) or atrial flutter on 12 lead electrocardiography at Screening Or\n* Patients with a history of PAF or atrial flutter, as documented by (telemetry, 12 lead electrocardiography or ambulatory \\[e.g. Holter\\] monitor) and not due to a reversible condition (e.g. alcohol binge drinking) can be entered even if they do not have PAF at Screening. There is not time-limit for this.\n* Patients with a Congestive heart failure, Hypertension, Age ( \\> 65 = 1 point, \\> 75 = 2 points), Diabetes, previous Stroke/transient ischemic attack (2 points) (CHA2DS2-VASc) risk score (tool as a predictor for estimating the risk of stroke in patients with atrial fibrillation (AF); Lip et al 2010) of 0-1 for men and 1-2 for women and in whom, in the investigator's judgment, the use of an anticoagulant for stroke prevention is not indicated\n\nExclusion Criteria:\n\n* History of stroke, transient ischemic attack or systemic embolism\n* History of major bleeding during treatment with an anticoagulant or antiplatelet therapy. (Patients who have had major bleeding on anticoagulants or antiplatelet therapy more than a year ago can be enrolled only if the bleeding was due to a reversible cause, e.g. gastro-duodenal ulcer that was successfully treated.)\n* History of traumatic or non-traumatic intracranial, intraspinal or intraocular bleeding\n* Known bleeding diathesis or any known active bleeding site at screening or baseline\n* Family history of bleeding disorder\n* Known active GI lesions predisposing to bleeding events\n* Myocardial infarction, unstable angina pectoris or coronary artery bypass graft (CABG) surgery within 12 months prior to the Screening period\n* Known clinically significant valvular heart disease including moderate or severe mitral stenosis (valve area \\<1.5 cm2)\n* Patients with a prosthetic heart valve\n\nOther protocol defined Inclusion/Exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Norman E Lepor, MD FACC FAHA FSCAI","affiliation":"Westside Medical Associates of Los Angeles","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Anthos Investigative Site","city":"Beverly Hills","state":"California","zip":"90211","country":"United States","geoPoint":{"lat":34.07362,"lon":-118.40036}},{"facility":"Anthos Investigative Site","city":"Wichita","state":"Kansas","zip":"67207","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"Anthos Investigative Site","city":"Alexandria","state":"Louisiana","zip":"71301","country":"United States","geoPoint":{"lat":31.31129,"lon":-92.44514}},{"facility":"Anthos Investigative Site","city":"Lansing","state":"Michigan","zip":"48912","country":"United States","geoPoint":{"lat":42.73253,"lon":-84.55553}},{"facility":"Anthos Investigative Site","city":"Wynnewood","state":"Pennsylvania","zip":"19096","country":"United States","geoPoint":{"lat":40.00289,"lon":-75.27074}},{"facility":"Anthos Investigative Site","city":"McKinney","state":"Texas","zip":"75069","country":"United States","geoPoint":{"lat":33.19762,"lon":-96.61527}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"28 participants were screened. 5 participants did not meet inclusion/exclusion criteria; 5 eligible participants failed randomization.","recruitmentDetails":"No subjects were enrolled in the optional Cohort 3.","groups":[{"id":"FG000","title":"Placebo","description":"Subcutaneous injection of placebo on Day 1, Day 31, and Day 61"},{"id":"FG001","title":"MAA868 120 mg","description":"Subcutaneous injection of 120 mg MAA868 on Day 1, Day 31, and Day 61"},{"id":"FG002","title":"MAA868 180 mg","description":"Subcutaneous injection of 180 mg MAA868 on Day 1, Day 31, and Day 61"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"7"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"6"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Placebo","description":"Subcutaneous injection of placebo on Day 1, Day 31, and Day 61"},{"id":"BG001","title":"MAA868 120 mg","description":"Subcutaneous injection of 120 mg MAA868 on Day 1, Day 31, and Day 61"},{"id":"BG002","title":"MAA868 180 mg","description":"Subcutaneous injection of 180 mg MAA868 on Day 1, Day 31, and Day 61"},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"18"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"52.2","spread":"18.79"},{"groupId":"BG001","value":"53.8","spread":"9.24"},{"groupId":"BG002","value":"58.1","spread":"8.34"},{"groupId":"BG003","value":"55.1","spread":"11.81"}]}]}]},{"title":"Age, Customized","paramType":"NUMBER","unitOfMeasure":"years","classes":[{"title":"18 to 20","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]}]},{"title":"21 to 30","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]},{"title":"31 to 40","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]}]},{"title":"41 to 50","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}]}]},{"title":"51 to 60","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"10"}]}]},{"title":"61 to 70","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"5"}]}]},{"title":"71 to 80","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]},{"title":"81 to 85","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"5"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"13"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"18"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"2"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"16"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Height","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"centimeters","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"182.01","spread":"5.573"},{"groupId":"BG001","value":"174.60","spread":"11.311"},{"groupId":"BG002","value":"175.74","spread":"8.337"},{"groupId":"BG003","value":"177.10","spread":"8.918"}]}]}]},{"title":"Weight","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kg","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"99.352","spread":"13.1715"},{"groupId":"BG001","value":"91.667","spread":"7.1102"},{"groupId":"BG002","value":"94.933","spread":"23.2745"},{"groupId":"BG003","value":"95.072","spread":"16.0115"}]}]}]},{"title":"Body mass index","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kg/m^2","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"30.022","spread":"4.1647"},{"groupId":"BG001","value":"30.392","spread":"4.7558"},{"groupId":"BG002","value":"30.887","spread":"8.6754"},{"groupId":"BG003","value":"30.482","spread":"6.1179"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants That Achieved More Than or Equal to 50%, 80%, and 90% Factor XI Inhibition at Trough After the Third Dose (Day 91) at Different Dose Levels of MAA868","description":"Number of participants achieving more than or equal to 50%, 80%, and 90% inhibition of factor XI (less than 50%, 20%, or 10% free factor XI) at trough after the third dose on Day 91 at different dose levels of MAA868","populationDescription":"Pharmacokinetic/Pharmacodynamic Set","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 91","groups":[{"id":"OG000","title":"Placebo","description":"Subcutaneous injection of placebo on Day 1, Day 31, and Day 61"},{"id":"OG001","title":"MAA868 120 mg","description":"Subcutaneous injection of 120 mg MAA868 on Day 1, Day 31, and Day 61"},{"id":"OG002","title":"MAA868 180 mg","description":"Subcutaneous injection of 180 mg MAA868 on Day 1, Day 31, and Day 61"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"}]}],"classes":[{"title":"More than or equal to 50% inhibition of factor XI","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"}]}]},{"title":"More than or equal to 80% inhibition of factor XI","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"More than or equal to 90% inhibition of factor XI","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving More Than or Equal to 50%, 80%, and 90% Factor XI Inhibition at Trough After First (Day 31) and Second Doses (Day 61) at Different Dose Levels of MAA868","description":"Number of participants achieving more than or equal to 50%, 80%, and 90% inhibition of factor XI (less than 50%, 20%, or 10% free factor XI) at trough on Day 31 (after first dose) and Day 61 (after second dose) at different dose levels of MAA868","populationDescription":"Pharmacokinetic/Pharmacodynamic Set","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 31 and Day 61","groups":[{"id":"OG000","title":"Placebo","description":"Subcutaneous injection of placebo on Day 1, Day 31, and Day 61"},{"id":"OG001","title":"MAA868 120 mg","description":"Subcutaneous injection of 120 mg MAA868 on Day 1, Day 31, and Day 61"},{"id":"OG002","title":"MAA868 180 mg","description":"Subcutaneous injection of 180 mg MAA868 on Day 1, Day 31, and Day 61"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"}]}],"classes":[{"title":"More than or equal to 50% factor XI inhibition : Day 31","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"5"}]}]},{"title":"More than or equal to 50% factor XI inhibition : Day 61","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"5"}]}]},{"title":"More than or equal to 80% factor XI inhibition : Day 31","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"}]}]},{"title":"More than or equal to 80% factor XI inhibition : Day 61","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"More than or equal to 90% factor XI inhibition : Day 31","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"More than or equal to 90% factor XI inhibition : Day 61","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"SECONDARY","title":"Overall Number of Participants Who Experienced Adverse Events, Including Serious Adverse Events, During the Treatment Period and Through End of Study","description":"Overall number of participants who experienced adverse events following multiple subcutaneous administration of MAA868 compared to placebo in participants with atrial fibrillation or atrial flutter","populationDescription":"Safety Set","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 through end of study, up to 170 days","groups":[{"id":"OG000","title":"Placebo","description":"Subcutaneous injection of placebo on Day 1, Day 31, and Day 61"},{"id":"OG001","title":"MAA868 120 mg","description":"Subcutaneous injection of 120 mg MAA868 on Day 1, Day 31, and Day 61"},{"id":"OG002","title":"MAA868 180 mg","description":"Subcutaneous injection of 180 mg MAA868 on Day 1, Day 31, and Day 61"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"}]}]}]},{"type":"SECONDARY","title":"Incidence of Major Bleeding Events, Clinically Relevant Non-major Bleeding Events and Total Bleeding With MAA868 Relative to Placebo","description":"Occurrence of confirmed major bleeding events, clinically relevant non-major bleeding events and total bleeding events during the treatment period","populationDescription":"Safety Set","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"incidence of events","timeFrame":"Day 1 through end of study, up to 170 days","groups":[{"id":"OG000","title":"Placebo","description":"Subcutaneous injection of placebo on Day 1, Day 31, and Day 61"},{"id":"OG001","title":"MAA868 120 mg","description":"Subcutaneous injection of 120 mg MAA868 on Day 1, Day 31, and Day 61"},{"id":"OG002","title":"MAA868 180 mg","description":"Subcutaneous injection of 180 mg MAA868 on Day 1, Day 31, and Day 61"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"}]}],"classes":[{"title":"Major bleeding events","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Clinically relevant non-major bleeding events","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Nuisance (not clinically relevant) bleeding events","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}]},{"title":"No bleeding events","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of MAA868","description":"Number of participants with anti-drug (MAA868) antibodies for all participants who received MAA868 120 mg or MAA868 180 mg.\n\n\"Non-evaluable observation\" refers to participants who had no sample collected (due to no visit or remote visit) or for whom the sample was not frozen.","populationDescription":"Safety Set","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Days 1, 31, 61, 71, 91, 121 and 170","groups":[{"id":"OG000","title":"MAA868 120 mg","description":"Subcutaneous injection of 120 mg MAA868 on Day 1, Day 31, and Day 61"},{"id":"OG001","title":"MAA868 180 mg","description":"Subcutaneous injection of 180 mg MAA868 on Day 1, Day 31, and Day 61"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"}]}],"classes":[{"title":"Baseline","categories":[{"title":"Negative","measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"}]},{"title":"Positive","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"Non-evaluable observation","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Day 1","categories":[{"title":"Negative","measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"}]},{"title":"Positive","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"Non-evaluable observation","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Day 31","categories":[{"title":"Negative","measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"}]},{"title":"Positive","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"Non-evaluable observation","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Day 61","categories":[{"title":"Negative","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"}]},{"title":"Positive","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"Non-evaluable observation","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}]}]},{"title":"Day 71","categories":[{"title":"Negative","measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"}]},{"title":"Positive","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"Non-evaluable observation","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"Day 91","categories":[{"title":"Negative","measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"}]},{"title":"Positive","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"Non-evaluable observation","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}]},{"title":"Day 121","categories":[{"title":"Negative","measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"}]},{"title":"Positive","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"Non-evaluable observation","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}]},{"title":"Day 170","categories":[{"title":"Negative","measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"}]},{"title":"Positive","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"Non-evaluable observation","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Adverse event information was collected at every study visit from providing written informed consent for participation in the study (on Days -28 to -3) until Day 170 (the end of study visit).","description":"The occurrence of adverse events was to be sought by non-directive questioning of the participants at each visit by the site staff during the study (e.g., \"How are you feeling today?\" or \"How have you been feeling since your last visit\") to elicit adverse event information from the participant. Adverse events might have been detected when they were volunteered by the participants during or between visits or through physical examination finding, laboratory test finding, or other assessments.","eventGroups":[{"id":"EG000","title":"Placebo","description":"Subcutaneous injection of placebo on Day 1, Day 31, and Day 61","deathsNumAffected":0,"deathsNumAtRisk":5,"seriousNumAffected":0,"seriousNumAtRisk":5,"otherNumAffected":4,"otherNumAtRisk":5},{"id":"EG001","title":"MAA868 120 mg","description":"Subcutaneous injection of 120 mg MAA868 on Day 1, Day 31, and Day 61","deathsNumAffected":0,"deathsNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"otherNumAffected":5,"otherNumAtRisk":6},{"id":"EG002","title":"MAA868 180 mg","description":"Subcutaneous injection of 180 mg MAA868 on Day 1, Day 31, and Day 61","deathsNumAffected":0,"deathsNumAtRisk":7,"seriousNumAffected":0,"seriousNumAtRisk":7,"otherNumAffected":3,"otherNumAtRisk":7}],"otherEvents":[{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (Version 22)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":7}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (Version 22)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (Version 22)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (Version 22)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (Version 22)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Version 22)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Version 22)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Dental caries","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Version 22)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Version 22)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Herpes simplex","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Version 22)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Otitis media","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Version 22)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Version 22)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Blood pressure increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (Version 22)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Coagulation test abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA (Version 22)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Eosinophil count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (Version 22)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (Version 22)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (Version 22)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (Version 22)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Renal impairment","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (Version 22)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (Version 22)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Atrial flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (Version 22)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (Version 22)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Version 22)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Prostatitis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA (Version 22)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Version 22)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Skin lesion","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (Version 22)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Haematoma","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (Version 22)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Gingival bleeding","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Version 22)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":7}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Investigator agrees that no submission for publication or public disclosure by the Investigator will be made until after publication of the results of the Multicenter Trial, except as set forth in the clinical trial agreement. If, however, there is no multicenter publication within eighteen (18) months after completion or termination of the Study, Investigator may publish or publicly present the Study Data in accordance with the clinical trial agreement."},"pointOfContact":{"title":"Debra Freedholm","organization":"Anthos Therapeutics","email":"Deb.f@anthostherapeutics.com","phone":"609-439-8246"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2020-05-10","uploadDate":"2021-11-09T10:19","filename":"Prot_000.pdf","size":7829282},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2021-03-18","uploadDate":"2021-11-09T10:09","filename":"SAP_001.pdf","size":4725691}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]}},"hasResults":true}